Wednesday, 28 Jun 2017

You are here

Responder Criteria for Nonpharmalogical Treatment of Fibromyalgia.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.
Due to the great variation in symptomatology among fibromyalgia patients, both pharmacological and nonpharmacological treatment for fibromyalgia are equally important while showing large individual variability in the long-term outcomes for fibromyalgia patients.

Responder criteria can help evaluate effectiveness of treatment and tailor to each individual patient, but no such criteria exists for nonpharmacological treatment per se.

Dr. Vervoort et al got on a mission to define responder criteria for multicomponent non-pharmacological treatment in FM.

In this project, candidate responder sets were identified in literature and tested for sensitivity and specificity in a cohort of 144 patients with FM receiving multicomponent non-pharmacological treatment. The therapist's judgement about patient's goal attainment and patients' perspective on health status change, assessed at 6 months after the start of treatment, were used as gold standard.

The groups defined 3 responder sets from the literature with the highest sensitivity and specificity. An additional 4 sets were formulated by expert group consensus: All responder criteria were defined and comprised combinations of domains of 1) pain; 2) fatigue; 3) patient global assessment (PGA); 4) illness perceptions; 5) limitations in activities of daily living (ADL); 6) sleep.

Of the literature-based responder sets, the OMERACT-OARSI responder set with patient's gold standard performed best (sensitivity 63%, specificity 75% and ROC area = 0.69). The expert-based responder set comprising the domains illness perceptions and limitations in ADL performed best (sensitivity 47%, specificity 96% and ROC area = 0.71).

Based on presented results, the group suggests further research should focus on the validation of those sets with acceptable performance.

 

 



Add new comment

More Like This

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.

Highlights from EULAR 2017 - From RheumReports.com

Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017. 

The RheumNow Week in Review – How to ACR/EULAR 23 June 2017

Dr. Jack Cush reviews his approach to attending and getting the most out of ACR or EULAR Congress meetings.

EULAR 2017 – Day 4 Highlights

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session. I reported on this in a video from day 4 (Saturday) called “Long-Term Comorbidities in JIA” – you can find it here.

Concomitant Septic Arthritis and Crystalline Arthropathy

Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.